Blog

Transitioning Biologics to Commercial Fill-Finish Manufacturing

From Clinic to Commercial Fill-Finish: A Guide for Biologic Manufacturing As biologic programmes transition from development to commercial fill-finish operations, the focus shifts from flexibility and speed to demonstrable understanding, validation, and lifecycle readiness. This phase is critical for ensuring […]

What HPAPI Containment Means in CDMO Selection

When a small molecule development programme involves a high-potency Active Pharmaceutical Ingredient (HPAPI), selecting the right Contract Development and Manufacturing Organisation (CDMO) becomes a decision with direct consequences for operator safety, product quality and regulatory compliance. Containment capability is not […]

Subscribe to our newsletter!

Get notified on our latest news.